Spero Therapeutics Inc
Company Profile
Business description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Contact
675 Massachusetts Avenue
14th Floor
CambridgeMA02139
USAT: +1 857 242-1600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
25
Stocks News & Analysis
stocks
This defensive ASX listed REIT offers a 5% yield
stocks
Chart of the Week: Anthropic’s IPO range sits below our fair value
stocks
Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,856.40 | 76.00 | -0.85% |
| CAC 40 | 8,146.83 | 69.95 | -0.85% |
| DAX 40 | 25,736.24 | 309.13 | -1.19% |
| Dow JONES (US) | 50,198.17 | 561.25 | -1.11% |
| FTSE 100 | 10,551.17 | 138.70 | -1.30% |
| HKSE | 22,892.29 | 402.46 | -1.73% |
| NASDAQ | 24,429.88 | 101.50 | 0.42% |
| Nikkei 225 | 58,934.69 | 89.59 | -0.15% |
| NZX 50 Index | 14,251.98 | 12.31 | -0.09% |
| S&P 500 | 7,323.63 | 16.90 | -0.23% |
| S&P/ASX 200 | 8,749.60 | 72.20 | -0.82% |
| SSE Composite Index | 3,553.84 | 33.99 | -0.95% |